These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

68 related items for PubMed ID: 1593599

  • 1. Immunity to cartilage proteoglycans.
    Banerjee S, Poole AR.
    J Rheumatol Suppl; 1992 Apr; 33():36-9. PubMed ID: 1593599
    [Abstract] [Full Text] [Related]

  • 2. Proteoglycan aggrecan-induced arthritis: a murine autoimmune model of rheumatoid arthritis.
    Glant TT, Mikecz K.
    Methods Mol Med; 2004 Apr; 102():313-38. PubMed ID: 15286393
    [Abstract] [Full Text] [Related]

  • 3. Critical roles of glycosaminoglycan side chains of cartilage proteoglycan (aggrecan) in antigen recognition and presentation.
    Glant TT, Buzás EI, Finnegan A, Negroiu G, Cs-Szabó G, Mikecz K.
    J Immunol; 1998 Apr 15; 160(8):3812-9. PubMed ID: 9558085
    [Abstract] [Full Text] [Related]

  • 4. Immunity to homologous collagens and cartilage proteoglycans in rabbits.
    Champion BR, Sell S, Poole AR.
    Immunology; 1983 Mar 15; 48(3):605-16. PubMed ID: 6600706
    [Abstract] [Full Text] [Related]

  • 5. Induction of arthritis in HLA-DR4-humanized and HLA-DQ8-humanized mice by human cartilage proteoglycan aggrecan but only in the presence of an appropriate (non-MHC) genetic background.
    Szántó S, Bárdos T, Szabó Z, David CS, Buzás EI, Mikecz K, Glant TT.
    Arthritis Rheum; 2004 Jun 15; 50(6):1984-95. PubMed ID: 15188376
    [Abstract] [Full Text] [Related]

  • 6. The role of immunity to cartilage proteoglycan in adjuvant arthritis. Intravenous injection of bovine proteoglycan enhances adjuvant arthritis.
    Van Vollenhoven RF, Soriano A, McCarthy PE, Schwartz RL, Garbrecht FC, Thorbecke GJ, Siskind GW.
    J Immunol; 1988 Aug 15; 141(4):1168-73. PubMed ID: 3260920
    [Abstract] [Full Text] [Related]

  • 7. Immune responses to cartilage link protein and the G1 domain of proteoglycan aggrecan in patients with osteoarthritis.
    Guerassimov A, Zhang Y, Cartman A, Rosenberg LC, Esdaile J, Fitzcharles MA, Poole AR.
    Arthritis Rheum; 1999 Mar 15; 42(3):527-33. PubMed ID: 10088776
    [Abstract] [Full Text] [Related]

  • 8. Achievement of a synergistic adjuvant effect on arthritis induction by activation of innate immunity and forcing the immune response toward the Th1 phenotype.
    Hanyecz A, Berlo SE, Szántó S, Broeren CP, Mikecz K, Glant TT.
    Arthritis Rheum; 2004 May 15; 50(5):1665-76. PubMed ID: 15146438
    [Abstract] [Full Text] [Related]

  • 9. Progressive polyarthritis induced in BALB/c mice by aggrecan from normal and osteoarthritic human cartilage.
    Glant TT, Cs-Szabó G, Nagase H, Jacobs JJ, Mikecz K.
    Arthritis Rheum; 1998 Jun 15; 41(6):1007-18. PubMed ID: 9627010
    [Abstract] [Full Text] [Related]

  • 10. Cellular immunity to the G1 domain of cartilage proteoglycan aggrecan is enhanced in patients with rheumatoid arthritis but only after removal of keratan sulfate.
    Guerassimov A, Zhang Y, Banerjee S, Cartman A, Leroux JY, Rosenberg LC, Esdaile J, Fitzcharles MA, Poole AR.
    Arthritis Rheum; 1998 Jun 15; 41(6):1019-25. PubMed ID: 9627011
    [Abstract] [Full Text] [Related]

  • 11. Mediators and autopathogenic effector cells in proteoglycan-induced arthritic and clinically asymptomatic BALB/c mice.
    Buzás EI, Mikecz K, Brennan FR, Glant TT.
    Cell Immunol; 1994 Oct 15; 158(2):292-304. PubMed ID: 7923385
    [Abstract] [Full Text] [Related]

  • 12. Antigenic mimicry between mycobacteria and cartilage proteoglycans: the model of adjuvant arthritis.
    van Eden W, Holoshitz J, Cohen I.
    Concepts Immunopathol; 1987 Oct 15; 4():144-70. PubMed ID: 3297334
    [No Abstract] [Full Text] [Related]

  • 13. T-cell recognition of differentially tolerated epitopes of cartilage proteoglycan aggrecan in arthritis.
    Buzás EI, Végvári A, Murad YM, Finnegan A, Mikecz K, Glant TT.
    Cell Immunol; 2005 Jun 15; 235(2):98-108. PubMed ID: 16185673
    [Abstract] [Full Text] [Related]

  • 14. VDIPEN, a metalloproteinase-generated neoepitope, is induced and immunolocalized in articular cartilage during inflammatory arthritis.
    Singer II, Kawka DW, Bayne EK, Donatelli SA, Weidner JR, Williams HR, Ayala JM, Mumford RA, Lark MW, Glant TT.
    J Clin Invest; 1995 May 15; 95(5):2178-86. PubMed ID: 7537757
    [Abstract] [Full Text] [Related]

  • 15. Cartilage proteoglycan-specific T cells as vectors of immunomodulatory biologicals in chronic proteoglycan-induced arthritis.
    Guichelaar T, ten Brink CB, van Kooten PJ, Berlo SE, Lafeber FP, Broeren CP, van Eden W, Broere F.
    Mol Immunol; 2008 Aug 15; 45(13):3526-35. PubMed ID: 18579208
    [Abstract] [Full Text] [Related]

  • 16. Major role for interleukin 1 but not for tumor necrosis factor in early cartilage damage in immune complex arthritis in mice.
    Van Lent PL, Van De Loo FA, Holthuysen AE, Van Den Bersselaar LA, Vermeer H, Van Den Berg WB.
    J Rheumatol; 1995 Dec 15; 22(12):2250-8. PubMed ID: 8835558
    [Abstract] [Full Text] [Related]

  • 17. Functional assessment of joint use in experimental inflammatory murine arthritis.
    Williams JM, Zurawski J, Mikecz K, Glant TT.
    J Orthop Res; 1993 Mar 15; 11(2):172-80. PubMed ID: 8483030
    [Abstract] [Full Text] [Related]

  • 18. [Heat-shock proteins and arthritis].
    Rijkers GT, de Graeff-Meeder E, Voorhorst-Ogink M, Zegers BJ, van Eden W.
    Tijdschr Kindergeneeskd; 1991 Oct 15; 59(5):178-82. PubMed ID: 1720264
    [Abstract] [Full Text] [Related]

  • 19. Variations in susceptibility to proteoglycan-induced arthritis and spondylitis among C3H substrains of mice: evidence of genetically acquired resistance to autoimmune disease.
    Glant TT, Bárdos T, Vermes C, Chandrasekaran R, Valdéz JC, Otto JM, Gerard D, Velins S, Lovász G, Zhang J, Mikecz K, Finnegan A.
    Arthritis Rheum; 2001 Mar 15; 44(3):682-92. PubMed ID: 11263784
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.